Theravance Biopharma, Inc.(TBPH)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Theravance Biopharma, Inc. (TBPH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TBPH at 69.2/100 on a 32-signal composite quality model, placing it at rank #280 of 2,960 stocks — the top 10% of the AI-ranked universe. TBPH scores in the top quartile across profitability (98.1), free cash flow (95.4), balance sheet strength (89.0). Areas of concern include institutional flow (7.9) and revenue scale (16.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Theravance Biopharma, Inc. reports quarterly revenue of $20.7M, net income of $-5.9M. Top institutional holders of TBPH by reported 13-F value include Madison Avenue Partners, Weiss Asset Management, BlackRock, based on the most recent SEC filings. TBPH trades on the Nasdaq exchange and files with the SEC under CIK 1583107. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TBPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Theravance Biopharma, Inc. directly from SEC EDGAR.
AI Quality Score
69.2/100
AI Rank
#280
Revenue
$20.7M
Net Income
$-5.9M
TBPH key financials by period
Theravance Biopharma, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$107.5M
$105.9M
-3.4%
FY 2024
10-K
$64.4M
$-56.4M
-72.9%
FY 2023
10-K
$57.4M
$-55.2M
-97.6%
FY 2022
10-K
$51.3M
$872.1M
-179.1%
FY 2021
10-K
$55.3M
$-199.4M
—
FY 2020
10-K
$71.9M
$-278.0M
—
Institutions holding TBPH
Institutional investors reporting a position in Theravance Biopharma, Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-11 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Theravance reported Q2 FY2026 revenue of $20.7M (-21% YoY) as it agreed to be acquired by Zymeworks for $17.00/share cash plus a CVR, while winding down its failed ampreloxetine program.
Biggest Revenue Drivers
Viatris collaboration agreement$20.7M+11% YoY
Higher YUPELRI net sales, which grew 7% YoY driven by 10% customer demand growth
Licensing and milestone revenue$0-100% YoY (NM)
Prior-year quarter included a one-time $7.5M milestone from YUPELRI's China NMPA approval; no milestone this quarter
Biggest Revenue Drivers
Total revenue: $20.7M-21% YoY
Viatris collaboration agreement$20.7M+11% YoY
Higher YUPELRI net sales, which grew 7% YoY driven by 10% customer demand growth
Licensing and milestone revenue$0-100% YoY (NM)
Prior-year quarter included a one-time $7.5M milestone from YUPELRI's China NMPA approval; no milestone this quarter
Largest Expense Items
Selling, general and administrative$14.2M-23% YoY
Cost savings from the Restructuring and lower pre-commercial CYPRESS launch spend
Transaction-related expenses$6.1MNM (vs. $0 PY)
Legal and financial advisory costs related to the Zymeworks Merger Agreement
Research and development$4.7M-55% YoY
Lower employee-related and external costs from the Restructuring and CYPRESS wind-down
Restructuring expenses$4.0MNM (vs. $0 PY)
One-time severance and equity-award modification costs from the March 2026 workforce reduction
Margins: No gross margin is presented; R&D and SG&A fell 55% and 23% YoY on Restructuring savings, but new Restructuring and Merger transaction costs widened the operating loss to $8.3M from $2.7M a year ago.
Watch Items from the Filing
Theravance agreed to be acquired by Zymeworks for $17.00/share cash plus a contingent value right; close expected H2 2026, subject to shareholder and regulatory approval.
Ampreloxetine's Phase 3 CYPRESS study missed its primary endpoint in March 2026, triggering a wind-down and ~50% reduction of the 90-employee workforce.
Total revenue is entirely dependent on the single Viatris/YUPELRI collaboration, with no other commercial products contributing.
A $32.5M termination fee is payable to Zymeworks if the Merger Agreement is terminated under specified circumstances.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
